This trial was powered for the primary safety and efficacy end points and for the change in mean 24-hour ambulatory systolic blood pressure at 6 months (secondary efficacy end point).
This trial was powered for the primary safety andefficacy end points and for the change in mean 24-hour ambulatory systolic blood pressure at6 months (secondary efficacy end point).